Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data

Table 2

Baseline characteristics of patients.

Characteristics	Elotuzumab group	Carfilzomib group	P value
	(n=321)	(n=396)
Age - yr
median	67	64	NC
range	37-88	38-87
Male sex - no. ()	192 (60)	215 (54)	0.16
ECOG performance status
0	159 (50)	165 (42)	0.08
1	138 (43)	191 (48)
2	24 (8)	40 (10)
Race - no.()
White	264 (82)	377 (95)	< 0.000
Others	57 (18)	19 (5)
Time since diagnosis - mo
median	41.6	36	NC
range	3.6-208.1	4.8-236.4
Disease stage (ISS) no. ()
I	141 (44)	64 (16)	< 0.000
II	102 (32)	99 (25)
III	66 (21)	185 (47)
unkown	12 (4)	48 (12)
Previous therapy regimens
median no.(range)	2 (1-4)	2 (1-3)	NC
regimens no.(%)
1	151 (47)	184 (47)	0.96
2 or more	170 (53)	211 (53)

: statistically significant.
NC: not calculable.